Biora's Preclinical Studies Show That The Company's Main Product, Emdogain, Induces Cell Death In Human Cancer Cells.Business Editors MALMO, Sweden--(BUSINESS WIRE)--March 27, 2000 Biora AB (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BIORY, SSE (1) An earlier full-screen editor in OS/2. (2) (Streaming SIMD Extensions) A series of additional instructions built into Pentium CPU chips for improved multimedia performance by performing mathematical operations on multiple sets of data at the : BIOR) today during an Investor's Day in Stockholm reported that the company's main product, Emdogain(R), induces programmed cell death pro·grammed cell death n. See apoptosis. programmed cell death proposed system of cell death, often including poly(ADP)-ribosylation, ensures that a cell will not survive if it is so badly damaged that its recovery would harm the in cultured human carcinoma cells. The finding is supported by the knowledge about Emdogain's mechanism of action that Biora has previously reported, where by it was shown that Emdogain promotes growth of attached connective tissue cells while many types of epithelial cells Epithelial cells Cells that form a thin surface coating on the outside of a body structure. Mentioned in: Corneal Transplantation are inhibited and cell-death occurs. Stina Gestrelius, Vice President of Research & Development, reported that Biora has applied for patent protection for the use of enamel matrix-derived polypeptides for induction of programmed cell death. Additional Research Projects Stina Gestrelius also presented another four Biora BioEx projects to persue the development of enamel matrix derivatives outside the oral cavity oral cavity n. The part of the mouth behind the teeth and gums that is bounded above by the hard and soft palates and below by the tongue and the mucous membrane connecting it with the inner part of the mandible. . These four projects which are all in the pre-clinical or early clinical phases, include: - healing of chronic wounds - improving graft integration - local bone formation - improving implant healing Newly acquired technology Biora's medical director Lars Heijl discussed Biora's newly acquired technology; a therapeutic for dry mouth (xerostomia xerostomia /xe·ro·sto·mia/ (zer?o-sto´me-ah) dryness of the mouth due to salivary gland dysfunction. xe·ro·sto·mi·a n. ). According to the present project plan Biora estimates that an application for regulatory approval can be submitted during the second quarter of 2003. Marketing The important work to build up a global, specialized dental marketing organization for Emdogain to market the approved indication approved indication, n 1. reliable signs that a certain remedy should be used. Not synonymous with “authorized.” 2. FDA-approved condition for a drug or other treatment that allows labeling. for surgical treatment of periodontal disease Periodontal Disease Definition Periodontal diseases are a group of diseases that affect the tissues that support and anchor the teeth. Left untreated, periodontal disease results in the destruction of the gums, alveolar bone (the part of the jaws where continues. The product is sold via wholly owned subsidiaries in the United States and in key markets in Europe. Biora has distribution agreements in other European, North- and South American and Asian markets. At the Investor's Day today Donna Janson, President of Biora's subsidiary in Biora's largest market USA, reported that the number of customer on the American market has during the first two months 2000 increased from 56 to 60 percent of the total customer target group, 4,000 periodontists. Customers who has bought more than once increased from 54 to 56 percent during the same period. Biora develops, manufactures and sells products for the treatment of periodontal disease and for use in oral surgery. Using its proprietary technology enad expertise, Biora aims to become a world leader in biology-based products for specialized dental therapy. Biora's American Depositary Shares are listed on the Nasdaq National Market in the US and Biora's ordinary shares are listed in the "O-list" of the Stockholm Stock Exchange The Stockholm Stock Exchange (Swedish: Stockholmsbörsen) is a stock exchange located in Stockholm, Sweden. Founded in 1863 [1] it is the primary securities exchange of the Nordic Countries. in Sweden. This press release may contain certain forward-looking statements that relate to future events or future business and financial performance. Such statements can only be predictions and the actual events or results may differ from those discussed. The Company cautions that these statements are subject to important factors that could cause actual results to differ materially from those expressed or implied in such forward looking statements and are more fully discussed in periodic reports filed with Securities and Exchange Commission. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion